Nothing Special   »   [go: up one dir, main page]

UY33864A - Novedoso Derivado Cristalino de Oxazina - Google Patents

Novedoso Derivado Cristalino de Oxazina

Info

Publication number
UY33864A
UY33864A UY0001033864A UY33864A UY33864A UY 33864 A UY33864 A UY 33864A UY 0001033864 A UY0001033864 A UY 0001033864A UY 33864 A UY33864 A UY 33864A UY 33864 A UY33864 A UY 33864A
Authority
UY
Uruguay
Prior art keywords
novel crystalline
oxazine derivative
oxazine
derivative
crystalline
Prior art date
Application number
UY0001033864A
Other languages
English (en)
Inventor
Ramos Rita
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of UY33864A publication Critical patent/UY33864A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

La invención se refiere a la [3- ((3R,6R)- 5- amino- 3,6- dimetil- 6- trifluorometil- 5 3,6-dihidro- 2H- [1,4]oxazin- 3- il)- 4- fluoro- fenil]- amida del ácido 5- ciano- 3- metil- piridina-2- carboxílico en forma cristalina, su preparación, su uso médico y medicamentos que contienen dicho compuesto en forma cristalina.
UY0001033864A 2011-01-12 2012-01-11 Novedoso Derivado Cristalino de Oxazina UY33864A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161432058P 2011-01-12 2011-01-12
US201161435088P 2011-01-21 2011-01-21

Publications (1)

Publication Number Publication Date
UY33864A true UY33864A (es) 2012-08-31

Family

ID=45833304

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001033864A UY33864A (es) 2011-01-12 2012-01-11 Novedoso Derivado Cristalino de Oxazina

Country Status (15)

Country Link
US (1) US8524897B2 (es)
EP (1) EP2663560A1 (es)
JP (1) JP2014502625A (es)
KR (1) KR20140051823A (es)
CN (1) CN103429588A (es)
AR (1) AR084832A1 (es)
AU (1) AU2012206633A1 (es)
BR (1) BR112013017757A2 (es)
CA (1) CA2824207A1 (es)
CY (1) CY1114757T1 (es)
EA (1) EA201391026A1 (es)
MX (1) MX2013008112A (es)
TW (1) TW201309685A (es)
UY (1) UY33864A (es)
WO (1) WO2012095451A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8637504B2 (en) 2008-06-13 2014-01-28 Shionogi & Co., Ltd. Sulfur-containing heterocyclic derivative having beta secretase inhibitory activity
UY32799A (es) 2009-07-24 2011-02-28 Novartis Ag Derivados de oxazina y su uso en el tratamiento de trastornos neurológicos
EP2485920B1 (en) 2009-10-08 2016-04-27 Merck Sharp & Dohme Corp. Pentafluorosulfur imino heterocyclic compounds as bace-1 inhibitors, compositions, and their use
EP2485591B1 (en) 2009-10-08 2016-03-23 Merck Sharp & Dohme Corp. Iminothiadiazine dioxide compounds as bace inhibitors, compositions, and their use
US8999980B2 (en) 2009-12-11 2015-04-07 Shionogi & Co., Ltd. Oxazine derivatives
CN106117193B (zh) 2011-01-13 2019-09-13 诺华股份有限公司 新的杂环衍生物及其在神经性疾病治疗中的应用
JP2016501827A (ja) 2012-10-24 2016-01-21 塩野義製薬株式会社 Ｂａｃｅ１阻害作用を有するジヒドロオキサジンまたはオキサゼピン誘導体
WO2018039062A1 (en) 2016-08-26 2018-03-01 Eli Lilly And Company 1,4-oxazines useful as selective bace1 inhibitors

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW385308B (en) 1994-03-04 2000-03-21 Merck & Co Inc Prodrugs of morpholine tachykinin receptor antagonists
AR043633A1 (es) 2003-03-20 2005-08-03 Schering Corp Ligandos de receptores de canabinoides
WO2005079802A1 (en) 2004-02-12 2005-09-01 Merck & Co., Inc. Bipyridyl amides as modulators of metabotropic glutamate receptor-5
TW200624426A (en) 2004-09-21 2006-07-16 Lilly Co Eli BACE inhibitors
US7888374B2 (en) 2005-01-28 2011-02-15 Abbott Laboratories Inhibitors of c-jun N-terminal kinases
WO2007049532A1 (ja) * 2005-10-25 2007-05-03 Shionogi & Co., Ltd. アミノジヒドロチアジン誘導体
MX2009009304A (es) 2007-03-01 2009-11-18 Novartis Ag Inhibidores de cinasa pim y metodos para su uso.
EP2689780A1 (en) 2007-04-24 2014-01-29 Shionogi & Co., Ltd. Intermediates for aminodihydrothiazine derivatives substituted with a cyclic group
JP5383483B2 (ja) * 2007-04-24 2014-01-08 塩野義製薬株式会社 アルツハイマー症治療用医薬組成物
GB0713686D0 (en) 2007-07-13 2007-08-22 Addex Pharmaceuticals Sa New compounds 2
ES2548774T3 (es) 2008-01-18 2015-10-20 Eisai R&D Management Co., Ltd. Derivado de aminodihidrotiazina condensado
US20100197688A1 (en) 2008-05-29 2010-08-05 Nantermet Philippe G Epha4 rtk inhibitors for treatment of neurological and neurodegenerative disorders and cancer
US8637504B2 (en) 2008-06-13 2014-01-28 Shionogi & Co., Ltd. Sulfur-containing heterocyclic derivative having beta secretase inhibitory activity
TW201028381A (en) 2008-07-14 2010-08-01 Shionogi & Co Pyridine derivative having ttk inhibition activity
CN102186841A (zh) 2008-10-22 2011-09-14 盐野义制药株式会社 具有bace1抑制活性的2-氨基嘧啶-4-酮及2-氨基吡啶衍生物
US9237972B2 (en) 2008-12-16 2016-01-19 Kimberly-Clark Worldwide, Inc. Liquid surfactant compositions that adhere to surfaces and solidify and swell in the presence of water and articles using the same
US8461160B2 (en) 2009-05-08 2013-06-11 Hoffmann-La Roche, Inc. Dihydropyrimidinones
UY32799A (es) 2009-07-24 2011-02-28 Novartis Ag Derivados de oxazina y su uso en el tratamiento de trastornos neurológicos
US8188079B2 (en) 2009-08-19 2012-05-29 Hoffman-La Roche Inc. 3-amino-5-phenyl-5,6-dihydro-2H-[1,4]oxazines
EP2500344A4 (en) 2009-11-13 2013-05-01 Shionogi & Co AMINOTHIAZIN OR AMINOOXAZINE DERIVATIVES WITH AN AMINO TERMINATION
US7964594B1 (en) 2009-12-10 2011-06-21 Hoffmann-La Roche Inc. Amino oxazine derivatives
UA103272C2 (uk) 2009-12-11 2013-09-25 Ф. Хоффманн-Ля Рош Аг 2-аміно-5,5-дифтор-5,6-дигідро-4h-оксазини як інгібітори bace1 і/або bace2
US8999980B2 (en) 2009-12-11 2015-04-07 Shionogi & Co., Ltd. Oxazine derivatives
JPWO2011077726A1 (ja) 2009-12-24 2013-05-02 塩野義製薬株式会社 ４−アミノ−１，３−チアジンまたはオキサジン誘導体
EP2519515B1 (en) 2009-12-31 2013-11-06 Novartis AG Pyrazine derivatives and their use in the treatment of neurological disorders
US8673894B2 (en) 2010-05-07 2014-03-18 Hoffmann-La Roche Inc. 2,5,6,7-tetrahydro-[1,4]oxazepin-3-ylamine or 2,3,6,7-tetrahydro-[1,4]oxazepin-5-ylamine compounds
BR112012031094A2 (pt) 2010-06-09 2016-10-25 Janssen Pharmaceutica Nv derivados de 5,6-di-hidro-2h-[1,4]oxazin-3-il-maina úteis como inibidores de beta-secretase (bace)
US20130079349A1 (en) 2010-06-09 2013-03-28 Janssen Pharmaceutica Nv 5-amino-3,6-dihydro-1h-pyrazin-2-one derivatives useful as inhibitors of beta-secretase (bace)
MA33509B1 (fr) 2010-07-13 2012-08-01 Novartis Ag Dérivés de l'oxazine et leur utilisation dans le traitement de troubles neurologiques

Also Published As

Publication number Publication date
EA201391026A1 (ru) 2013-12-30
JP2014502625A (ja) 2014-02-03
CA2824207A1 (en) 2012-07-19
WO2012095451A1 (en) 2012-07-19
US20120178745A1 (en) 2012-07-12
KR20140051823A (ko) 2014-05-02
CN103429588A (zh) 2013-12-04
AR084832A1 (es) 2013-06-26
TW201309685A (zh) 2013-03-01
MX2013008112A (es) 2013-10-01
EP2663560A1 (en) 2013-11-20
BR112013017757A2 (pt) 2016-10-11
US8524897B2 (en) 2013-09-03
CY1114757T1 (el) 2016-12-14
AU2012206633A1 (en) 2013-08-01

Similar Documents

Publication Publication Date Title
UY34523A (es) Derivados de betulina
UY34365A (es) Compuestos heterociclicos
UY33958A (es) Inhibidores de la glucosilceramida sintasa
UY34206A (es) Anticuerpo monoclonal de interleucina-31
IN2014CN02639A (es)
UY33936A (es) Derivados de fluoro-piridinona útiles como agentesantibacterianos.
CR20140024A (es) Compuestos inhibidores de metaloenzimas
UY33930A (es) Inhibidores novedosos de quinasas
UY34550A (es) Bencilpirazoles sustituidos
UY34092A (es) Nuevos compuestos como inhibidores de jak
UY34145A (es) Compuestos inhibidores de metaloenzimas
CL2012002979A1 (es) Derivados de n3-sustituido-n1-sulfonil-5-fluorpirimidinona.
UY34472A (es) Derivados modificados de 4-fenil-piridina
UY34602A (es) ?Derivados de bencimidazolil- e imidazopiridinil-metilamina?
CR20130539A (es) Triazolopiridinas
UY34654A (es) Inhibidores de la beta-secretasa
CR20140468A (es) Inhibidores de diacilglicerol aciltransferasa 2
UY34074A (es) Composición oftálmica de olopatadina altamente concentrada
UY33929A (es) Compuestos de ciclohexilo tetrasustituido como inhibidores de quinasas
UY34027A (es) Inhibidores sustituidos de acetil-coa carboxilasa.
BR112014003027A2 (pt) formulação herbicida melhorada
UY34119A (es) Montaje machihembrado de fijación
UY33864A (es) Novedoso Derivado Cristalino de Oxazina
CR20120637A (es) Triazolopiridinas sustituidas
CR20130419A (es) Derivados heterocíclicos de amina

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20200422